[1] Marr KA, Carter RA, Crippa F, et al.Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients[J].Clin Infect Dis, 2002, 34(7):909-917.
[2] Pagano L, Caira M, Candoni A, et al.The epidemiology of fungal infections in patients with hematologic malignancies:the SEIFEM-2004 study[J].Haematologica, 2006, 91(8):1068-1075.
[3] Kamai Y, Chiang LY, Lopes BLM, et al.Interactions of Aspergillus fumigatus with vascular endothelial cells[J].Med Mycol, 2006, 44(Suppl 1):S115-117.
[4] Gonzlez GA, Moreno CM, de la Pea JL P.Current diagnosis and treatment of Castleman's disease[J].Rev Clin Esp, 2016, 216(3):146-156.
[5] Revest M, Patrat-Delon S, Devillers A, et al.Contribution of 18fluoro-deoxyglucose PET/CT for the diagnosis of infectious diseases[J].Med Mal Infect, 2014, 44(6):251-260.
[6] Hot A, Maunoury C, Poiree S, et al.Diagnostic contribution of positron emission tomography with fluorodeoxyglucose for invasive fungal infections[J].Clin Microbiol Infect, 2011, 17(3):409-417.
[7] Ok M, Einsele H, Loeffler J.Genetic susceptibility to Aspergillus fumigatus infections[J].Int J Med Microbiol, 2011, 301(5):445-452.
[8] Mezger M, Einsele H, Loeffler J.Genetic susceptibility to infections with Aspergillus fumigatus[J].Crit Rev Microbiol, 2010, 36(2):168-177.
[9] Walsh TJ, Anaissie EJ, Denning DW, et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J].Clin Infect Dis, 2008, 46(3):327-360.
[10] Maschmeyer G, Haas A, Cornely OA.Invasive aspergillosis:epidemiology, diagnosis and management in immunocompromised patients[J].Drugs, 2007, 67(11):1567-1601.